北京维通利华实验动物技术有限公司是Charles River Laboratories的在华合资企业，也是一家集动物生产、研发和服务于一身的高新技术企业。公司有建筑面积36,000m2的生产设施，年产符合SPF/VAF标准的啮齿类实验动物400余万只，涵盖40多个品系，遗传背景清晰，是客户长期选择的实验动物生产供应商。

在维通利华，我们一直努力营造舒适的工作环境，建立和谐的工作氛围。本着尊重人才而不迷信经验的原则，维通利华为员工提供展示自己能力的机会和适合的发展平台，并通过岗位轮转和培训等多种方式，使员工加快成长。我们期望您的加入，成为我们事业上的伙伴，与企业一起在奋斗中成长、壮大！

Charles River Laboratories成立于1947年，总部位于美国马萨诸塞州威明顿，目前在世界18个国家建立了70个分支机构，员工人数12,000名，实验动物供应量占50%。作为一家上市公司，Charles River Laboratories致力于为制药企业、生物技术公司、政府机构及科研院所提供产品及服务，加速其研究和药物发展进程。

更多信息请登录 www.vitalriver.com

About Charles River

Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.

With over 11,000 employees within 70 facilities in 18 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges. Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world. And in 2016, revenue increased by 23.3% to $1.68 billion from $1.36 billion in 2015.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of ~70% of the drugs approved by the FDA in 2016.